Global Proliferative Diabetic Retinopathy (PDR) Market
Healthcare Services

What’s Driving Growth in the Proliferative Diabetic Retinopathy (PDR) Market? Insights into Key Trends and Opportunities

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What key factors are powering the surge in the proliferative diabetic retinopathy (pdr) market right now?

The proliferative diabetic retinopathy (PDR) market has seen substantial growth, forecasted to increase from $2.42 billion in 2024 to $2.7 billion in 2025 at a CAGR of 11.6%. Historical growth was driven by the rising prevalence of diabetes, lifestyle changes and unhealthy diets, government initiatives, and the increasing number of diabetes-related vision loss cases.

How fast Is the proliferative diabetic retinopathy (pdr) market expected to grow, and what’s its future value?

The proliferative diabetic retinopathy (PDR) market is projected to witness robust growth, reaching $4.02 billion in 2029 at a CAGR of 10.5%. Growth factors include an aging population, increased public awareness of diabetes, R&D funding, and a rising demand for combination therapies. Key trends include improvements in diagnostic technologies, treatment innovations, AI-driven early diagnosis, gene therapy advancements, and enhanced retinal imaging.

Get your proliferative diabetic retinopathy (pdr) market report here!

https://www.thebusinessresearchcompany.com/report/proliferative-diabetic-retinopathy-pdr-global-market-report

What are the leading drivers of growth in the proliferative diabetic retinopathy (pdr) market?

The growth of the proliferative diabetic retinopathy (PDR) market is anticipated to be propelled by the increasing instances of diabetes. Diabetes is a persistent medical disorder where the blood contains excessive glucose (sugar) levels. Diabetes is the primary cause of the proliferative diabetic retinopathy disease, for which there are several treatment methods available to prevent further damage to the retina and preserve vision. For instance, the National Health Service (NHS), a UK-based government department, revealed in June 2024, that there was a substantial rise amongst those under 40, from 173,166 in 2022 to 216,440 in 2023. The sudden increase points to a worrying trend in this age group and suggests a quick surge in diabetes incidence among younger populations. Thus, the upsurge in diabetes cases is fueling the growth of the proliferative diabetic retinopathy (PDR) market. The proliferative diabetic retinopathy (PDR) market’s potential growth is likely to be influenced by the increasing occurrence of obesity. Obesity is a multifaceted, long-term disease with several roots leading to surplus body fat and often, poor health. It is connected with insulin resistance, continuous minor inflammation, and increased oxidative stress, which can harm the retinal microvasculature and contribute to proliferative diabetic retinopathy’s onset. The Trust for America’s Health, a non-profit organization headquartered in the US, stated in their 2022 report that obesity rates in the US keep rising, with four out of ten American adults being obese. This is a marked increase from the previous year, as 19 states now have adult obesity rates over 35%, a climb from 16 states last year. Consequently, the escalating occurrence of obesity is catalyzing the expansion of the proliferative diabetic retinopathy (PDR) market.

What are the key segments defining the proliferative diabetic retinopathy (pdr) market?

The proliferative diabetic retinopathy (PDR) market covered in this report is segmented –

1) By Treatment Type: Anti-VEGF (Vascular Endothelial Growth Factor) Therapy, Intraocular Steroids, Laser Surgery, Vitrectomy

2) By Mode of Administration: Injectables, Oral, Other Mode Of Administrations

3) By Application: Hospitals, Clinics, Other Applications

Subsegments:

1) By Anti-VEGF Therapy: Aflibercept, Ranibizumab, Bevacizumab

2) By Intraocular Steroids: Triamcinolone Acetonide, Dexamethasone Implant, Fluocinolone Acetonide

3) By Laser Surgery: Focal Laser Photocoagulation, Panretinal Laser Photocoagulation

4) By Vitrectomy: Pars Plana Vitrectomy, Anterior Vitrectomy

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12911&type=smp

Who are the key players steering the development of the proliferative diabetic retinopathy (pdr) market?

Major companies operating in the proliferative diabetic retinopathy (pdr) market are Pfizer Inc., Johnson and Johnson Limited, F. Hoffmann-La Roche Ltd., Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Merck KGaA, Kubota Vision Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Santen Pharmaceutical Co. Ltd., Lupin Limited, Genentech Inc., Sirnaomics Inc.

What emerging trends are influencing the growth of the proliferative diabetic retinopathy (pdr) market?

Prominent firms in the proliferative diabetic retinopathy market are consistently devoted to the innovation of new therapies in an effort to augment the efficacy of treatment, lessen the treatment burden, and enhance patient results. For instance, in June 2022, Biogen, a biotech corporation based in the US, and Samsung Bioepis, a South Korean biotech firm, launched Byooviz (ranibizumab-nuna), the inaugural ophthalmology biosimilar in the US. These commodities are utilized for the treatment of patients suffering from diabetic macular edema, proliferative diabetic retinopathy, neovascular age-related macular degeneration (wet AMD), and choroidal neovascularization.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12911

Which regions are most influential in expanding the proliferative diabetic retinopathy (pdr) market?

North America was the largest region in the proliferative diabetic retinopathy market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in proliferative diabetic retinopathy (PDR) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Similar Reports By The Business Research Company:

Pet Diabetes Care Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/pet-diabetes-care-devices-global-market-report

Insulin Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/insulin-drugs-global-market-report

Smart Insulin Pens Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/smart-insulin-pens-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Leave a Reply

Your email address will not be published. Required fields are marked *